BioMarin has announced that it is pulling Roctavian, its gene therapy for adults with severe hemophilia A, from the market. The company reported that demand for the therapy remained far below expectations, leading to significant financial losses and the decision to discontinue commercial availability.
BioMarin’s withdrawal of Roctavian represents a significant moment for the hemophilia community. While gene therapy remains a promising area of research, this development highlights the need for treatments that balance innovation with long‑term effectiveness, safety, and accessibility.
Read the full article here
